Post Reply
21-40 of 4174
your wish never come true. haha
tofudidi ( Date: 09-Dec-2021 11:04) Posted:
|
DBS Group Research
09 Dec 2021
PCR Test Providers
New saliva ART has the potential to displace PCR testing
Singapore has developed a saliva antigen rapid test (ART) that is as accurate as the PCR test
The self-administered test has an accuracy of 97% and is able to detect different COVID-19 viral variants, including Omicron
The test only takes around 15 minutes, which is the same as the shortest time needed for current ARTs. Current PCR tests can take between a few hours and three days
The test kit may be sold in the market in as soon as three months, and we believe that it has the potential to displace the current PCR testing
We view this as negative for Raffles Medical and Q & M Dental Group which currently conduct PCR tests in Singapore
Raffles Medical is currently a key PCR test provider at Changi Airport while Q& M also conducts PCR tests but is not involved in on-arrival testing
09 Dec 2021
PCR Test Providers
New saliva ART has the potential to displace PCR testing
Singapore has developed a saliva antigen rapid test (ART) that is as accurate as the PCR test
The self-administered test has an accuracy of 97% and is able to detect different COVID-19 viral variants, including Omicron
The test only takes around 15 minutes, which is the same as the shortest time needed for current ARTs. Current PCR tests can take between a few hours and three days
The test kit may be sold in the market in as soon as three months, and we believe that it has the potential to displace the current PCR testing
We view this as negative for Raffles Medical and Q & M Dental Group which currently conduct PCR tests in Singapore
Raffles Medical is currently a key PCR test provider at Changi Airport while Q& M also conducts PCR tests but is not involved in on-arrival testing
then u short now lo. later will gain profit
tofudidi ( Date: 09-Dec-2021 11:04) Posted:
|
1 day wonder. later will crash back to near opening price
Biolidics to start producing new Covid-19 Neutralising Antibody Rapid Test Kit by year-end
&bull Biolidics has entered into a definitive manufacturing agreement for the production of its ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit (the " ClearEpi NAB Test" ) and obtained the relevant product liability insurance
&bull Unlike most commercially available COVID-19 serology tests which test for IgM/ IgG antibodies in patients, the ClearEpi NAB Test, developed by Biolidics with technology licensed from the Agency for Science, Technology and Research (" A*STAR" )&rsquo s Accelerate Technologies Pte Ltd (&ldquo A*ccelerate&rdquo ), provides results that may indicate an individual' s protective immunity against COVID-19
&bull Neutralising antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
&bull The ClearEpi NAB Test can potentially serve as an important tool to assist in the area of assessing vaccine efficacy, vaccine deployment and social activities management (such as air travel2), among others
&bull The commercialisation of ClearEpi NAB Test is another Singapore medical technology innovation that showcases the strong collaborative partnerships between Singapore public agencies and the private sector
&bull The ClearEpi NAB Test has obtained the CE marking that allows it to be marketed and sold in the European Union
Biolidics Limited (&ldquo Biolidics&rdquo or the &ldquo Company&rdquo and together with its subsidiaries, the &ldquo Group&rdquo ), a medical technology company with a focus on innovative diagnostic solutions, is pleased to announce that it had on 8 December 2021: (i) entered into a definitive agreement with its contract manufacturer for the production of the ClearEpi NAB Test and (ii) obtained the relevant product liability insurance for the ClearEpi NAB Test. The ClearEpi NAB Test was developed by Biolidics with technology licensed from A*STAR&rsquo s A*ccelerate.
The commercial production for the ClearEpi NAB Test by the Company is expected to commence in the current financial year ending 31 December 2021.
The clinical validation of the ClearEpi NAB Test was undertaken in Singapore. Biolidics engaged A*STAR Infectious Disease Labs (ID Labs) for the screening of the prototype, as part of the clinical validation of the ClearEpi NAB Test conducted by Biolidics. ID Labs is an A*STAR research institute set up in April 2021 to undertake disease-specific research efforts within A*STAR.
On 20 September 2021, the Group announced that it has developed the ClearEpi NAB Test that is intended for qualitative detection of neutralising antibodies in serum or plasma which provides an indication of the individual' s protective immunity against COVID-19 infection.
Most commercially available serology tests against COVID-19, including the Company&rsquo s COVID-19 Antibody Test Kit launched on 30 March 2020, test for the presence of IgM/IgG antibodies. The presence of IgM/IgG antibodies indicates whether an individual has been previously infected. Not all antibodies have neutralising or &ldquo disarming&rdquo capacity.
Neutralising antibodies, on the other hand bind to regions of the virus that &ldquo disarm&rdquo or prevent infection directly. The presence of neutralising antibodies provides indications that an individual has protective immunity against infection1,3. Nonetheless, it is important to note that information is still emerging from researches in relation to the level of antibodies sufficient to confer protective immunity to an individual, and how long such protective immunity against COVID-19 may last in an individual.
In addition, the Group announced on 20 September 2021 that it had received confirmation for the CE marking for the ClearEpi NAB Test which enables the Company to market and sell the ClearEpi NAB Test in the European Union.
Mr Song Tang Yih (宋 丹 昱 ), Executive Director and Chief Executive Officer of Biolidics, said, &ldquo As the COVID-19 pandemic becomes endemic, we believe that our ClearEpi NAB Test can become a vital tool in assessing vaccine candidates and formulate vaccine deployment strategies (such as the need for additional booster doses).
With our ClearEpi NAB Test, the testing of neutralising antibodies may also serve as a guide for government agencies to accelerate the re-opening of the economy, social activities and global travel."
Wow, a quick run to hit 0.21 as within contra period... all out. Must exercise caution as this is a one day or at most two day wonder. Will wait for the correction b4 re-entry. All huat big....
Dyodd
Dyodd
niteowl68 ( Date: 30-Nov-2021 10:45) Posted:
|
flush out short term etailers, chart looking gd, 35 ct easy target easywin
easywin ( Date: 09-Dec-2021 09:41) Posted:
|
at 205 / 210 many profit taking liow
breakout , should hit all time high 34 ct with such good news
lets see.... BB playing
Sgvale ( Date: 09-Dec-2021 09:39) Posted:
|
1 day wonder
next target 30
shk363 ( Date: 08-Dec-2021 21:23) Posted:
|
Price up sustainable?
Those who bought, did you even study it's financial stats?
why worry? the furture is all about testing testing and testing........
eric998 ( Date: 09-Dec-2021 09:23) Posted:
|
Most important is how much money can this bring to the profits?
SmallSmall ( Date: 08-Dec-2021 21:02) Posted:
|
last year this counter amazingly rose up to 8xx...
tomorrow easily clear 20
UPDATE ON BIOLIDICS CLEAREPI SARS-COV-2 NEUTRALISING ANTIBODY RAPID TEST KIT
&bull Biolidics has entered into a definitive manufacturing agreement for the production of its ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit (the " ClearEpi NAB Test" ) and obtained the relevant product liability insurance
&bull Unlike most commercially available COVID-19 serology tests which test for IgM/ IgG antibodies in patients, the ClearEpi NAB Test, developed by Biolidics with technology licensed from the Agency for Science, Technology and Research (" A*STAR" )&rsquo s Accelerate Technologies Pte Ltd (&ldquo A*ccelerate&rdquo ), provides results that may indicate an individual' s protective immunity against COVID-19
&bull Neutralising antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection1
&bull The ClearEpi NAB Test can potentially serve as an important tool to assist in the area of assessing vaccine efficacy, vaccine deployment and social activities management (such as air travel2), among others
&bull The commercialisation of ClearEpi NAB Test is another Singapore medical technology innovation that showcases the strong collaborative partnerships between Singapore public agencies and the private sector
&bull The ClearEpi NAB Test has obtained the CE marking that allows it to be marketed and sold in the European Union
Singapore, 8 December 2021 &ndash Biolidics Limited
&bull Biolidics has entered into a definitive manufacturing agreement for the production of its ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit (the " ClearEpi NAB Test" ) and obtained the relevant product liability insurance
&bull Unlike most commercially available COVID-19 serology tests which test for IgM/ IgG antibodies in patients, the ClearEpi NAB Test, developed by Biolidics with technology licensed from the Agency for Science, Technology and Research (" A*STAR" )&rsquo s Accelerate Technologies Pte Ltd (&ldquo A*ccelerate&rdquo ), provides results that may indicate an individual' s protective immunity against COVID-19
&bull Neutralising antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection1
&bull The ClearEpi NAB Test can potentially serve as an important tool to assist in the area of assessing vaccine efficacy, vaccine deployment and social activities management (such as air travel2), among others
&bull The commercialisation of ClearEpi NAB Test is another Singapore medical technology innovation that showcases the strong collaborative partnerships between Singapore public agencies and the private sector
&bull The ClearEpi NAB Test has obtained the CE marking that allows it to be marketed and sold in the European Union
Singapore, 8 December 2021 &ndash Biolidics Limited